CY1121406T1 - Διαγνωση καρδιακης ανεπαρκειας - Google Patents

Διαγνωση καρδιακης ανεπαρκειας

Info

Publication number
CY1121406T1
CY1121406T1 CY20191100229T CY191100229T CY1121406T1 CY 1121406 T1 CY1121406 T1 CY 1121406T1 CY 20191100229 T CY20191100229 T CY 20191100229T CY 191100229 T CY191100229 T CY 191100229T CY 1121406 T1 CY1121406 T1 CY 1121406T1
Authority
CY
Cyprus
Prior art keywords
heart failure
concentration
igfbp2
diagnosis
patient
Prior art date
Application number
CY20191100229T
Other languages
Greek (el)
English (en)
Inventor
Philippe Rouet
Fatima SMIH-ROUET
Franck Desmoulin
Michel Galinier
Original Assignee
Institut National De La Santé Et De La Recherche Médicale (Inserm)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National De La Santé Et De La Recherche Médicale (Inserm) filed Critical Institut National De La Santé Et De La Recherche Médicale (Inserm)
Publication of CY1121406T1 publication Critical patent/CY1121406T1/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4745—Insulin-like growth factor binding protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44704—Details; Accessories
    • G01N27/44717—Arrangements for investigating the separated zones, e.g. localising zones
    • G01N27/4473—Arrangements for investigating the separated zones, e.g. localising zones by electric means
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Electrochemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Peptides Or Proteins (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • External Artificial Organs (AREA)
  • Paper (AREA)
CY20191100229T 2012-08-09 2019-02-25 Διαγνωση καρδιακης ανεπαρκειας CY1121406T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305988 2012-08-09
PCT/EP2013/066697 WO2014023820A1 (en) 2012-08-09 2013-08-09 Diagnostic of heart failure
EP13747847.5A EP2883057B1 (en) 2012-08-09 2013-08-09 Diagnostic of heart failure

Publications (1)

Publication Number Publication Date
CY1121406T1 true CY1121406T1 (el) 2020-05-29

Family

ID=48953397

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100229T CY1121406T1 (el) 2012-08-09 2019-02-25 Διαγνωση καρδιακης ανεπαρκειας

Country Status (16)

Country Link
US (2) US20150219669A1 (enExample)
EP (1) EP2883057B1 (enExample)
JP (2) JP6298054B2 (enExample)
CY (1) CY1121406T1 (enExample)
DK (1) DK2883057T3 (enExample)
ES (1) ES2713098T3 (enExample)
HR (1) HRP20190341T1 (enExample)
HU (1) HUE042708T2 (enExample)
LT (1) LT2883057T (enExample)
PL (1) PL2883057T3 (enExample)
PT (1) PT2883057T (enExample)
RS (1) RS58553B1 (enExample)
SI (1) SI2883057T1 (enExample)
SM (1) SMT201900108T1 (enExample)
TR (1) TR201902555T4 (enExample)
WO (1) WO2014023820A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2725906T3 (es) * 2013-06-06 2019-09-30 Inst Nat Sante Rech Med Biomarcador de rehospitalización tras insuficiencia cardíaca
JP7401442B2 (ja) * 2018-01-31 2023-12-19 イントラ-セルラー・セラピーズ・インコーポレイテッド 新規使用
US12699104B2 (en) * 2019-11-06 2026-08-04 National University Corporation Kagawa University Heart failure marker
CN120053474B (zh) * 2025-02-26 2025-12-12 浙江大学 辅酶a在制备心肌细胞铁死亡抑制剂中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060183681A1 (en) * 2005-02-14 2006-08-17 Bio-Rad Laboratories, Inc. Stabilized compositions containing natriuretic peptides
JP4465469B2 (ja) * 2005-02-21 2010-05-19 国立大学法人佐賀大学 循環器病マーカーとしてのインターロイキン13
EP1722232A1 (en) * 2005-05-09 2006-11-15 F.Hoffmann-La Roche Ag Devices and methods for diagnosing or predicting early stage cardiac dysfunctions
US20080166734A1 (en) * 2005-12-21 2008-07-10 David Xing-Fei Deng Genes and methods of using the same for diagnosis and for targeting the therapy of cardiovascular disease
WO2008005469A2 (en) 2006-06-30 2008-01-10 Schering Corporation Igfbp2 biomarker
DK2115477T3 (en) 2007-01-25 2015-08-10 Hoffmann La Roche USE OF IGFBP-7 IN THE EVIDENCE OF HEART FAILURE
EP2310860A1 (en) * 2008-07-30 2011-04-20 INSERM - Institut National de la Santé et de la Recherche Médicale Blood glutathione as a biomarker for screening asymptomatic patients at risk for heart failure
PT2829881T (pt) * 2010-07-14 2017-11-29 Commw Scient Ind Res Org Diagnóstico para cancro colo-rectal
ES2627337T3 (es) * 2010-08-26 2017-07-27 F. Hoffmann-La Roche Ag Uso de biomarcadores para controlar una medicación en un sujeto que padece insuficiencia cardíaca
EP2841945A4 (en) 2012-04-24 2016-04-27 Astute Medical Inc METHOD AND COMPOSITIONS FOR DIAGNOSIS AND FORECASTING OF STROKE OR OTHER BRAINS
US20140206632A1 (en) * 2013-01-22 2014-07-24 Singulex, Inc. Endothelin in the Diagnosis of Cardiac Disease

Also Published As

Publication number Publication date
JP2018109640A (ja) 2018-07-12
PT2883057T (pt) 2019-03-06
TR201902555T4 (tr) 2019-03-21
ES2713098T3 (es) 2019-05-17
LT2883057T (lt) 2019-04-25
HRP20190341T1 (hr) 2019-05-31
SMT201900108T1 (it) 2019-05-10
WO2014023820A1 (en) 2014-02-13
DK2883057T3 (en) 2019-03-18
SI2883057T1 (sl) 2019-07-31
EP2883057B1 (en) 2018-12-05
JP2015528562A (ja) 2015-09-28
US11061037B2 (en) 2021-07-13
JP6298054B2 (ja) 2018-03-20
HUE042708T2 (hu) 2019-07-29
US20180143208A1 (en) 2018-05-24
JP6595641B2 (ja) 2019-10-23
RS58553B1 (sr) 2019-05-31
US20150219669A1 (en) 2015-08-06
PL2883057T3 (pl) 2019-07-31
EP2883057A1 (en) 2015-06-17

Similar Documents

Publication Publication Date Title
CY1121872T1 (el) Αξιολογηση, δοκιμασιες και θεραπεια των pkal-μεσολαβουμενων διαταραχων
MX362514B (es) Kits y ensayos de diagnostico para la deteccion del receptor 1 de folato.
TR201906285T4 (tr) İntraoperatif otolog kan kurtarımından tümör hücrelerinin giderilmesi.
MX2017014381A (es) Metodos terapeuticos y diagnosticos para cancer.
BR112013010023A2 (pt) algoritimo aperfeiçoado para a detecção de diabetes
CY1119262T1 (el) Αναλυτικες μεθοδοι και συστοιχιες για χρηση στην ταυτοποιηση παραγοντων που επαγουν ευαισθητοποιηση στο ανθρωπινο δερμα
MX2016006252A (es) Tratamiento o prevencion de afecciones pulmonares con monoxido de carbono.
EA201391587A1 (ru) Комбинированная терапия на основе hsp90
EP3236262A3 (en) Surrogate functional diagnostics test for cancer
MX355416B (es) Biomarcadores de cancer de pulmon y usos de los mismos.
MX368099B (es) Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
CY1121916T1 (el) Βιοδεικτες micro-rna για την ταυτοποιηση του κινδυνου και/ή τη διαγνωση του ογκου στον πνευμονα
MX386919B (es) Composiciones, métodos y kits para el diagnóstico de una neoplasia neuroendocrina gastroenteropancreática.
CY1122360T1 (el) Μεθοδος για τη διαγνωση της νοσου niemann-pick
EA201490883A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛА К α-СИНУКЛЕИНУ ДЛЯ ДИАГНОСТИКИ ПОВЫШЕННОГО УРОВНЯ α-СИНУКЛЕИНА В МОЗГЕ
EA201690537A1 (ru) Способы и средства для введения контрастной среды
EA201700123A1 (ru) Способ прогнозирования варианта лекарственного препарата для лечения депрессии
BR112018011224A2 (pt) processo de avaliação do risco de complicações nos pacientes que apresentam uma síndrome da resposta inflamatória sistêmica (sirs)
CY1122033T1 (el) Μεθοδοι για την αυξηση του βιaιa εκπνεομενου ογκου σε ασθματικους με τη χρηση μπενραλιζουμαμπης
RU2013138721A (ru) Способы и наборы для прогнозирования риска дыхательной недостаточности, почечной недостаточности или тромбопении у пациента, страдающего сепсисом, путем измерения уровней эндокана в крови
CY1120063T1 (el) Αντισωματα κατα του ανθρωπινου dlk-1 που εχει δραση κατα των ογκων in vivo
CY1119653T1 (el) Μεθοδος για ταυτοποιηση της ευαισθησιας ενος ασθενους σε θεραπεια αναστολης της τελομερασης
MX2015001788A (es) Metabolitos de metionina predicen la evolución agresiva del cáncer.
MX2015015023A (es) Metodo para la determinacion de cobre libre.
EA201491780A1 (ru) Мутанты c-raf, придающие резистентность к ингибиторам raf